Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.

Arrowhead Pharmaceuticals (ARWR) has just gained FDA approval for REDEMPLO, its first-ever approved drug and the first siRNA therapy available for familial chylomicronemia syndrome. This regulatory ...

The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...

Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...

The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...

Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

An announcement from Arrowhead Pharmaceuticals ( ($ARWR) ) is now available. On November 18, 2025, Arrowhead Pharmaceuticals announced that the ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken ...

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the ...

“The INTASYL siRNA technology represents a promising approach to enhance cancer treatment.” said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. “Further the INTASYL compound PH ...

Yukireen xiyyaarota waraanaa saffisoo Raafaal F4 jedhaman Faransaayitti hojjataman 100 ta'an akkasumas sirna ittisa ...